|Application:||Gene expression microarray analysis|
|Number of samples:||22|
|Release date:||Jan 1 2012|
|Last update date:||Jul 26 2018|
|Diseases:||Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Neoplasms|
|Chemicals:||Amino Acids, Aspartic Acid, Cysteine|
|Dataset link||Substitutions in the KRas oncogene determine protein behavior: Implications for signaling and clinical outcome.|
Gene expression profiles were measured in 22 core biopsies from patients with refractory non-small cell lung cancer included in the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE). All tumors were KRAS mutants, but with different patterns of amino acid substitutions. Supervised analysis of transcriptome profiling was performed to compare cysteine or valine KRAS mutants with other KRAS mutants.